Dosing & Uses
Cardiomyopathy
Pending FDA approval for transthyretin-mediated amyloid cardiomyopathy (ATTR-CM)
Next:
Pharmacology
Mechanism of Action
Selectively binds to transthyretin tetramer to prevent transthyretin transport protein destabilization and amyloid formation that causes ATTR-CM
Previous
Next:
Images
No images available for this drug.
Previous
Next:
Medscape prescription drug monographs are based on FDA-approved labeling information, unless otherwise noted, combined with additional data derived from primary medical literature.
